Literature DB >> 33471354

A review of Ciclesonide in COVID-19. Still a long way to go.

Kunal Deokar1, Mehul Agarwal2, Naveen Dutt2, Nishant Chauhan2, Ram Niwas2, Benhur Joel Shadrach2, Gopal Chawla2.   

Abstract

As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.

Entities:  

Keywords:  COVID 19; ciclesonide; repurposed drug

Year:  2021        PMID: 33471354     DOI: 10.5603/ARM.a2020.0173

Source DB:  PubMed          Journal:  Adv Respir Med        ISSN: 2451-4934


  3 in total

1.  Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial.

Authors:  Jiro Terada; Retsu Fujita; Takuya Kawahara; Yasutaka Hirasawa; Taku Kinoshita; Yuichiro Takeshita; Yuri Isaka; Toru Kinouchi; Hiroshi Tajima; Yuji Tada; Kenji Tsushima
Journal:  EClinicalMedicine       Date:  2022-06-03

Review 2.  An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).

Authors:  Armina Alagheband Bahrami; Ali Azargoonjahromi; Samin Sadraei; Aryan Aarabi; Zahra Payandeh; Masoumeh Rajabibazl
Journal:  Cell Mol Biol Lett       Date:  2022-05-13       Impact factor: 8.702

Review 3.  COVID-19 and corticosteroids: a narrative review.

Authors:  Gaber El-Saber Batiha; Ali I Al-Gareeb; Hebatallah M Saad; Hayder M Al-Kuraishy
Journal:  Inflammopharmacology       Date:  2022-05-13       Impact factor: 5.093

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.